Terms: = Kidney tumors AND CUX1, ENSG00000160967, P39880, p75, p200, p110, p100, Nbla10317, CUX, COY1, CDP, CASP, 1523
57 results:
1. Risk of bladder, kidney and prostate cancer from occupational exposure to welding fumes: a systematic review and meta-analysis.
Collatuzzo G; Hamdani M; Boffetta P
Int Arch Occup Environ Health; 2024 Apr; 97(3):221-230. PubMed ID: 38231405
[TBL] [Abstract] [Full Text] [Related]
2. A prospective head-to-head comparison of [
Wang G; Li L; Zhu M; Zang J; Wang J; Wang R; Yan W; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3126-3136. PubMed ID: 37233785
[TBL] [Abstract] [Full Text] [Related]
3. FAK-mediated phosphorylation at Y464 regulates p85β nuclear translocation to promote tumorigenesis of ccRCC by repressing RB1 expression.
Zhang Y; He B; Zhang D; Zhang Y; Chen C; Zhang W; Yang S; Yao M; Cui G; Gu J; Wang T; Lin Z; Fan Y; Xiong Z; Hao Y
Cell Rep; 2023 Mar; 42(3):112188. PubMed ID: 36857183
[TBL] [Abstract] [Full Text] [Related]
4. Preliminary experience of oblique occlusion technique in robot-assisted infrahepatic inferior vena cava thrombectomy: step-by-step procedures and short term outcomes.
Liu Z; Li Y; Tang S; Zhao X; Chen K; Ge L; Zhu G; Hong P; Wu B; Wu Z; Zhang S; Tian X; Wang S; Liu C; Zhang H; Ma L
BMC Surg; 2022 Nov; 22(1):377. PubMed ID: 36333708
[TBL] [Abstract] [Full Text] [Related]
5. Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment.
Abbas ZS; Sulaiman GM; Jabir MS; Mohammed SAA; Khan RA; Mohammed HA; Al-Subaiyel A
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889394
[TBL] [Abstract] [Full Text] [Related]
6. Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs.
Matsuda Y; Yamashita T; Ye J; Yasukawa M; Yamakawa K; Mukai Y; Machitani M; Daigo Y; Miyagi Y; Yokose T; Oshima T; Ito H; Morinaga S; Kishida T; Minamoto T; Yamada S; Takei J; Kaneko MK; Kojima M; Kaneko S; Masaki T; Hirata M; Haba R; Kontani K; Kanaji N; Miyatake N; Okano K; Kato Y; Masutomi K
J Pathol; 2022 Jun; 257(2):172-185. PubMed ID: 35094384
[TBL] [Abstract] [Full Text] [Related]
7. Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1-a systematic review.
Junker T; Duus L; Rasmussen BSB; Azawi N; Lund L; Graumann O; Nørgaard B
Syst Rev; 2022 Jan; 11(1):4. PubMed ID: 34983648
[TBL] [Abstract] [Full Text] [Related]
8. Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute.
Akgul M; Al-Obaidy KI; Cheng L; Idrees MT
J Clin Pathol; 2022 Nov; 75(11):772-775. PubMed ID: 34168073
[TBL] [Abstract] [Full Text] [Related]
9. Small renal masses in Latin-American population: characteristics and prognostic factors for survival, recurrence and metastasis - a multi-institutional study from LARCG database.
Mourão TC; Abreu D; Carvalhal GF; Gueglio G; da Costa WH; Calsavara VF; Meza-Montoya L; Bengió RG; Scorticati C; Castillejos-Molina R; Rodríguez-Covarrubias F; Autran-Gómez AM; Campos-Salcedo JG; Nolazco A; Ameri C; Zampolli H; Langenhin R; Muguruza D; Machado MT; Mingote P; Clavijo J; Nogueira L; Clark O; Rovegno AR; Secin FP; Decia R; Guimarães GC; Glina S; Rodríguez-Faba O; Palou J; Zequi SC
BMC Urol; 2020 Jul; 20(1):85. PubMed ID: 32615971
[TBL] [Abstract] [Full Text] [Related]
10. The Role of O
Zhang W; Liu M; Li Y; Song S; Li K; Ma Y
Pathol Oncol Res; 2020 Apr; 26(2):1201-1209. PubMed ID: 31190217
[TBL] [Abstract] [Full Text] [Related]
11. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract] [Full Text] [Related]
12. Papillary pattern in clear cell renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 23 cases.
Alaghehbandan R; Ulamec M; Martinek P; Pivovarcikova K; Michalova K; Skenderi F; Hora M; Michal M; Hes O
Ann Diagn Pathol; 2019 Feb; 38():80-86. PubMed ID: 30502717
[TBL] [Abstract] [Full Text] [Related]
13. Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases.
Ding Y; Wang C; Li X; Jiang Y; Mei P; Huang W; Song G; Wang J; Ping G; Hu R; Miao C; He X; Chen G; Li H; Zhu Y; Zhang Z
Diagn Pathol; 2018 Aug; 13(1):54. PubMed ID: 30111351
[TBL] [Abstract] [Full Text] [Related]
14. Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study.
Hasegawa T; Yamanaka T; Gobara H; Miyazaki M; Takaki H; Sato Y; Inaba Y; Yamakado K
Jpn J Radiol; 2018 Sep; 36(9):551-558. PubMed ID: 29968201
[TBL] [Abstract] [Full Text] [Related]
15. Nuclear factor-kappa B subunits and their prognostic cancer-specific survival value in renal cell carcinoma patients.
Ng KL; Yap NY; Rajandram R; Small D; Pailoor J; Ong TA; Razack AH; Wood ST; Morais C; Gobe GC
Pathology; 2018 Aug; 50(5):511-518. PubMed ID: 29935727
[TBL] [Abstract] [Full Text] [Related]
16. Hospital volume and outcomes of robot-assisted partial nephrectomy.
Xia L; Pulido JE; Chelluri RR; Strother MC; Taylor BL; Raman JD; Guzzo TJ
BJU Int; 2018 Jun; 121(6):900-907. PubMed ID: 29232025
[TBL] [Abstract] [Full Text] [Related]
17. Patient preference for stereotactic radiosurgery plus or minus whole brain radiotherapy for the treatment of brain metastases.
Zeng KL; Raman S; Sahgal A; Soliman H; Tsao M; Wendzicki C; Chow E; Lo SS
Ann Palliat Med; 2017 Dec; 6(Suppl 2):S155-S160. PubMed ID: 28866900
[TBL] [Abstract] [Full Text] [Related]
18. [Comparison of paired box genes 8 and 2 expression in epithelium tissues and the related tumors].
Song Y; Huang X; Shen GH; Liu XY; Zhang X
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):424-428. PubMed ID: 28635231
[No Abstract] [Full Text] [Related]
19. Tumor Necrosis Factor: Function, Release and Clearance.
Bemelmans MHA; van Tits LJH; Buurman WA
Crit Rev Immunol; 2017; 37(2-6):249-259. PubMed ID: 29773022
[TBL] [Abstract] [Full Text] [Related]
20. Tumor detection using magnetosome nanoparticles functionalized with a newly screened EGFR/HER2 targeting peptide.
Xiang Z; Yang X; Xu J; Lai W; Wang Z; Hu Z; Tian J; Geng L; Fang Q
Biomaterials; 2017 Jan; 115():53-64. PubMed ID: 27888699
[TBL] [Abstract] [Full Text] [Related]
[Next]
